Oxbow Advisors LLC Buys 450 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Oxbow Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,941 shares of the biopharmaceutical company’s stock after buying an additional 450 shares during the period. Oxbow Advisors LLC’s holdings in Gilead Sciences were worth $6,645,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. Valued Wealth Advisors LLC increased its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the 4th quarter valued at approximately $29,000. Finally, Crews Bank & Trust bought a new position in Gilead Sciences during the 4th quarter valued at approximately $31,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $109.95 on Friday. The business’s fifty day moving average is $95.41 and its 200 day moving average is $88.63. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $111.03. The company has a market capitalization of $137.03 billion, a PE ratio of 297.16, a price-to-earnings-growth ratio of 0.90 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.94 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is presently 832.43%.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of analyst reports. The Goldman Sachs Group raised their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Bank of America reissued a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Mizuho lifted their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $80.00 to $120.00 in a report on Tuesday. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 713,000 shares of company stock worth $67,945,181 over the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.